CAMP4 Q2 net loss $33.5M; CMP-002 trial cleared in Australia/Argentina; $50.1M raised

Camp4 Therapeutics Corp

Net loss $33.5M vs $12.6M YoY; includes $20.9M non-cash loss on derivative tranche liability.
Cash $86.4M at June 30, 2026; plus $50.1M from second closing extends runway to end 2028.
Regulatory clearance from TGA/HREC (Australia) and ANMAT (Argentina) for Phase 1/2 CMP-002 trial; initiation expected Q4 2026.
R&D expenses $10.8M vs $10.3M; G&A $4.3M vs $4.2M.
HQ relocated to Watertown, Mass.; Analyst Day Sept 28, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.